

d his

(FILE 'USPAT' ENTERED AT 07:55:33 ON 25 AUG 93)

L1 437 S LAV OR ARV
L2 1020 S RETROVIR?
L3 290 S L1 AND L2
L4 1183 S HIV
L5 515 S L4 AND L2
L6 588 S L3 OR L5
L7 141123 S 1983-1984/FY
L8 2 S L6 AND L7

=> d 1-2

1. 4,716,102, Dec. 29, 1987, Purified AIDS-associated virus **ARV**-2;
Jay A. Levy, 435/5, 243, 810, 974, 975; 436/518, 528, 543, 808, 809, 811,
825, 826 [IMAGE AVAILABLE]

2. 4,665,032, May 12, 1987, Human T cell hybridomas which produce
immunosuppressive factors; Jeffrey C. Laurence, 435/240.26, 70.2, 172.2,
948; 530/380; 935/101 [IMAGE AVAILABLE]

=> log y
U.S. Patent & Trademark Office LOGOFF AT 07:59:42 ON 25 AUG 93

d his

(FILE 'USPAT' ENTERED AT 08:01:49 ON 25 AUG 93)
L1 730 S HTLV
L2 1020 S RETROVIR?
L3 477 S L1 AND L2
L4 141123 S 1983-1984/FY
L5 13 S L3 AND L4

=> d 1-13

1. 4,740,463, Apr. 26, 1988, Methods and artificial genes for antagonizing the function of an oncogene; Robert A. Weinberg, et al., 435/172.3, 91, 320.1; 536/23.5, 24.1 [IMAGE AVAILABLE]
2. 4,738,922, Apr. 19, 1988, Trans-acting transcriptional factors; William A. Haseltine, et al., 435/69.3, 69.1, 91, 172.3, 320.1; 536/23.72, 24.2; 935/32, 34, 39 [IMAGE AVAILABLE]
3. 4,716,102, Dec. 29, 1987, Purified AIDS-associated virus ARV-2; Jay A. Levy, 435/5, 243, 810, 974, 975; 436/518, 528, 543, 808, 809, 811, 825, 826 [IMAGE AVAILABLE]
4. 4,707,439, Nov. 17, 1987, Screening test for reverse-transcriptase containing virus such as non-A, non-B hepatitis, NANBH; Belinda P. Seto, et al., 435/5; 424/3; 435/4, 6; 436/820; 935/76 [IMAGE AVAILABLE]
5. 4,692,403, Sep. 8, 1987, Methods and compositions for the detection of acquired immune deficiency syndrome; Luther E. Lindner, et al., 435/5; 424/86; 435/7.21, 7.24, 188, 968, 974; 436/501, 519, 547, 804, 811, 813; 530/389.4, 391.3 [IMAGE AVAILABLE]
6. 4,665,032, May 12, 1987, Human T cell hybridomas which produce immunosuppressive factors; Jeffrey C. Laurence, 435/240.26, 70.2, 172.2, 948; 530/380; 935/101 [IMAGE AVAILABLE]
7. 4,663,436, May 5, 1987, Leukemia-associated virus immunogen, vaccine and assay; John H. Elder, et al., 530/324; 424/88; 530/325, 326, 327, 328, 329, 330; 930/220 [IMAGE AVAILABLE]
8. 4,652,599, Mar. 24, 1987, Method of continuous production of **retroviruses** (**HTLV**-III) from patients with AIDS and pre-AIDS using permissive cells; Robert C. Gallo, et al., 435/239, 5, 29, 240.2, 240.26, 948; 436/527 [IMAGE AVAILABLE]
9. 4,647,773, Mar. 3, 1987, Method of continuous production of **retroviruses** (**HTLV**-III) from patients with AIDS and pre-AIDS; Robert C. Gallo, et al., 435/239; 424/89; 435/235.1, 240.26, 948 [IMAGE AVAILABLE]
10. 4,645,738, Feb. 24, 1987, Method for differential diagnosis of T cell leukemias using monoclonal antibodies; Robert W. Knowles, et al., 435/7.23, 7.24, 960; 436/502, 519, 520, 536, 537, 548, 811, 813; 935/104, 106, 108, 110 [IMAGE AVAILABLE]
11. 4,639,371, Jan. 27, 1987, Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom; Alfred M. Prince, et al., 424/86, 85.8, 89, 450; 530/380, 389.4, 403, 415, 417, 421, 806 [IMAGE AVAILABLE]
12. 4,588,681, May 13, 1986, Process for producing adult T cell leukemia-associated antigen; Tatsushi Sawada, et al. 425/5, 422/61; 424/8A;

435/7.23, 7.9, 810, 948, 961, 975; 436/519, 523, 536, 542, 543, 804, 808, 811 [IMAGE AVAILABLE]

13. 4,520,113, May 28, 1985, Serological detection of antibodies to **HTLV**-III in sera of patients with AIDS and pre-AIDS conditions; Robert C. Gallo, et al., 435/5; 422/61; 424/86, 89; 435/7.92, 194, 239, 810, 948, 974, 975; 436/504, 515, 530, 531, 543, 546, 804, 808, 809, 811 [IMAGE AVAILABLE]

=> d 8 ab

US PAT NO: 4,652,599 [IMAGE AVAILABLE]

LS: 8 of 13

ABSTRACT:

A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic **retroviruses** (**HTLV**-family) with cytopathic effects (**HTLV**-III) from patients with the acquired immune deficiency syndrome (AIDS), pre-AIDS and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with **HTLV**-III, which is transformed and provides T-cell populations which are highly susceptible to and permissive for **HTLV**-III, and convenient for large scale production, isolation, and biological detection of the virus. Other operational neoplastic T-cell lines which are positive for OKT4 marker, e.g., Molt 3, CEM, Ti7.4 and HUT78, can produce **HTLV**-III in a large amount and retain its unlimited capability for growth.

=> log y

U.S. Patent & Trademark Office LOGOFF AT 08:05:44 ON 25 AUG 93